stoxline Quote Chart Rank Option Currency Glossary
TFF Pharmaceuticals, Inc. (TFFP)
2.5445  -0.066 (-2.51%)    04-23 11:16
Open: 2.57
High: 2.9
Volume: 24,186
Pre. Close: 2.61
Low: 2.5445
Market Cap: 6(M)
Technical analysis
2024-04-23 11:21:56 AM
Short term     
Mid term     
Targets 6-month :  9.05 1-year :  12.84
Resists First :  7.75 Second :  11
Pivot price 3.76
Supports First :  2.5 Second :  2.08
MAs MA(5) :  2.94 MA(20) :  4.34
MA(100) :  6.46 MA(250) :  8.73
MACD MACD :  -1.1 Signal :  -1
%K %D K(14,3) :  3.5 D(3) :  2.8
RSI RSI(14): 24.7
52-week High :  21.25 Low :  2.5
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ TFFP ] has closed above bottom band by 12.5%. Bollinger Bands are 8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 3.08 - 3.11 3.11 - 3.13
Low: 2.46 - 2.49 2.49 - 2.51
Close: 2.54 - 2.6 2.6 - 2.63
Company Description

TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's lead drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It is also developing other dry powder products, such as cannabidiol substance for the treatment of various epilepsy syndromes, as well as anxiety, insomnia, and various pain; Inhaled SARS-CoV2 Monoclonal Antibody for the treatment of patients with COVID-19 infections; Niclosamide Inhalation Powder to treat tapeworm infections in humans, as well as COVID-19 disease; and other vaccines. The company has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs; a joint development agreement with Augmenta Bioworks, Inc. to develop inhaled SARS-CoV2 monoclonal antibody; and a licensing and collaboration agreement with UNION therapeutics A/S. The company was incorporated in 2018 and is based in Austin, Texas.

Headline News

Mon, 15 Apr 2024
TFF Pharmaceuticals reports promising Phase 2 trial data By -

Mon, 15 Apr 2024
TFF Pharmaceuticals Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF TAC) Phase 2 ... - GlobeNewswire

Tue, 02 Apr 2024
Healthcare Stocks Moving Up and Down Tuesday: NXL, CARM, QTTB, ACB, VERV, TFFP, CDIO, PTPI - InvestorsObserver

Mon, 01 Apr 2024
TFF Pharmaceuticals Full Year 2023 Earnings: Misses Expectations - Simply Wall St

Thu, 28 Mar 2024
TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results - Yahoo Finance

Tue, 26 Mar 2024
Is TFF Pharmaceuticals Inc (TFFP) a Leader in the Biotechnology Industry? - InvestorsObserver

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 0 (M)
Shares Float 3 (M)
Held by Insiders 2.23e+006 (%)
Held by Institutions 4.7 (%)
Shares Short 18 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -2.139e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -4 %
Return on Assets (ttm) 695.8 %
Return on Equity (ttm) -75.8 %
Qtrly Rev. Growth 733870 %
Gross Profit (p.s.) -49.15
Sales Per Share -101.51
EBITDA (p.s.) 0
Qtrly Earnings Growth -11.9 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -16 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.03
Price to Cash Flow 0.85
Stock Dividends
Dividend 0
Forward Dividend 86600
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android